IRIDEX

OverviewSuggest Edit

A worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 60 independent distributors into over 100 countries.
TypePublic
Founded1989
HQMountain View, USMap
Websiteiridex.com
Employee Ratings3.2More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)94(-17%)
Revenue (FY, 2019)$43.4 M(+2%)
Share Price (Nov 2020)$1.7 (+2%)
Cybersecurity ratingAMore

IRIDEX Office Locations

IRIDEX has an office in Mountain View
Mountain View, US (HQ)
1212 Terra Bella Ave
Show all (1)

IRIDEX Financials and Metrics

IRIDEX Revenue

Embed Graph
View revenue for all periods
IRIDEX's revenue was reported to be $43.45 m in FY, 2019
USD

Net income (Q2, 2020)

(2.8m)

Market capitalization (20-Nov-2020)

23.2m

Closing stock price (20-Nov-2020)

1.7

Cash (27-Jun-2020)

11.6m

EV

16.6m
IRIDEX's current market capitalization is $23.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

33.2m33.9m38.3m42.8m41.8m46.2m41.6m42.6m43.4m

Revenue growth, %

12%(2%)11%

Cost of goods sold

16.9m17.5m19.7m21.4m21.8m25.3m26.1m25.1m25.5m

Gross profit

16.3m16.3m18.6m21.4m20.0m20.8m15.5m17.5m17.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.8m10.8m8.3m8.4m7.9m8.9m9.2m9.5m10.3m10.6m10.1m9.8m10.8m9.0m11.9m11.9m9.8m10.5m10.0m10.9m9.5m10.3m11.3m10.6m10.4m10.7m9.0m

Cost of goods sold

5.9m5.9m4.3m4.3m4.0m4.7m4.7m4.8m5.3m5.3m5.0m5.0m5.4m4.8m6.6m6.2m5.5m6.0m5.5m6.5m5.6m6.0m6.7m6.3m5.9m6.4m5.1m

Gross profit

4.9m4.9m4.0m4.1m3.9m4.2m4.5m4.7m5.1m5.3m5.1m4.8m5.4m4.2m5.3m5.7m4.2m4.5m4.5m4.4m3.9m4.3m4.6m4.3m4.5m4.3m3.9m

Gross profit Margin, %

45%45%48%49%50%47%49%50%49%50%51%49%50%47%44%48%43%43%45%40%41%41%40%40%44%40%43%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

10.8m11.9m13.4m13.3m10.0m23.7m21.7m21.2m12.7m

Accounts Receivable

5.6m5.5m7.9m9.1m9.3m

Prepaid Expenses

464.0k1.1m500.0k547.0k401.0k

Inventories

6.7m8.0m10.6m9.1m11.1m11.6m9.4m8.8m8.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.9m9.5m13.9m13.8m13.7m11.6m13.5m14.1m14.0m12.9m13.0m10.2m13.1m12.2m10.5m11.5m9.6m23.9m24.6m22.8m18.5m16.0m23.7m17.2m15.6m12.9m11.1m11.6m

Accounts Receivable

7.5m7.7m5.1m5.9m5.5m6.0m6.1m5.7m6.7m7.3m9.3m8.5m7.9m8.9m7.0m7.4m6.4m7.1m8.4m8.4m8.1m8.8m7.0m5.8m

Prepaid Expenses

571.0k1.2m1.2m1.1m1.1m1.1m534.0k730.0k586.0k425.0k560.0k1.2m568.0k488.0k671.0k681.0k653.0k492.0k766.0k593.0k590.0k691.0k508.0k

Inventories

10.2m10.2m7.0m7.5m7.5m8.1m8.9m10.0m9.9m9.8m9.6m11.2m9.9m10.2m11.1m12.1m12.7m11.7m11.4m10.7m9.3m9.1m8.7m8.7m9.0m8.9m8.2m7.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

2.6m1.4m2.2m10.0m474.0k(11.7m)(12.9m)(12.8m)(8.8m)

Depreciation and Amortization

410.0k427.0k490.0k420.0k522.0k648.0k858.0k809.0k688.0k

Inventories

(981.0k)(1.4m)(2.5m)1.5m(2.0m)(537.0k)2.1m463.0k545.0k

Accounts Payable

66.0k525.0k173.0k(520.0k)465.0k(229.0k)(270.0k)788.0k76.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

1.5m1.8m1.6m1.9m1.2m874.0k1.3m1.8m487.0k784.0k490.0k442.0k246.0k(652.0k)101.0k(227.0k)(898.0k)(1.9m)(4.6m)(7.7m)(3.6m)(6.9m)(10.0m)(3.0m)(5.5m)(7.3m)(1.7m)(4.4m)

Depreciation and Amortization

203.0k307.0k113.0k203.0k310.0k126.0k240.0k364.0k108.0k239.0k142.0k291.0k461.0k207.0k417.0k660.0k193.0k395.0k617.0k211.0k354.0k518.0k143.0k277.0k

Inventories

(1.0m)(995.0k)(446.0k)(1.1m)(1.1m)(112.0k)(905.0k)(2.0m)747.0k852.0k9.6m11.2m9.9m10.2m(36.0k)(1.0m)(1.6m)(85.0k)255.0k974.0k75.0k282.0k533.0k66.0k(207.0k)(188.0k)(35.0k)278.0k

Accounts Payable

118.0k241.0k(36.0k)559.0k(51.0k)(825.0k)468.0k(28.0k)(508.0k)(270.0k)1.8m2.6m2.5m2.1m473.0k971.0k249.0k(50.0k)(214.0k)(130.0k)252.0k519.0k828.0k(116.0k)(320.0k)(86.0k)(1.1m)(2.0m)
show all
USDQ2, 2012

Financial Leverage

1.4 x
Show all financial metrics

IRIDEX Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

Learn more about our premium products
SecurityScorecard logo

IRIDEX Online and Social Media Presence

IRIDEX's Trends

Embed Graph

IRIDEX News and Updates

April 02, 2019

Ken Ludlum Appointed to IRIDEX Board of Directors

MOUNTAIN VIEW, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Ken Ludlum has been appointed to its Board of Directors, effective …
March 05, 2019

IRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results

MOUNTAIN VIEW, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018.
January 21, 2019

Ophthalmic Lasers Global Market 2018: Key Players – Abbott Laboratories, Carl Zeiss, Ellex Medical Lasers, IRIDEX Corporation, Lumenis Ltd.

Ophthalmic Lasers -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024 Posted via Industry Today. Follow us on Twitter @IndustryToday
January 08, 2019

IRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year

MOUNTAIN VIEW, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018.
October 23, 2018

Leading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAO

Glaucoma and Retina Specialists Will Discuss the Benefits of MicroPulse® Technology
October 22, 2018

Medical Laser Systems Market 2018 Global Analysis By Key Players – Alcon, Cynosure, IRIDEX, Lumenis, Syneron Medical

WiseGuyReports.Com Publish a New Market Research Report On –“ Medical Laser Systems Market 2018 Global Analysis By Key Players – Alcon, Cynosure, IRIDEX, Lumenis, Syneron Medical”. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

IRIDEX Blogs

November 09, 2020

IRIDEX Announces Third Quarter 2020 Financial Results

MOUNTAIN VIEW, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020 . Third Quarter Summary Total revenue of $8.8 million , a decline of 17% versus $10.7 million in the prior year period, and an
October 26, 2020

IRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020

MOUNTAIN VIEW, Calif. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020 . The Company’s management team will host a corresponding
August 06, 2020

IRIDEX Announces Second Quarter 2020 Financial Results

MOUNTAIN VIEW, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020 . Second Quarter Summary Total revenue declined 40% to $6.2 million versus $10.4 million in the prior year period Cost control
July 23, 2020

IRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020

IRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020 Content Import Thu, 07/23/2020 - 16:07 IRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020 07/23/20 This release is a backfill from a News Wire Genera…
May 11, 2020

IRIDEX Announces First Quarter 2020 Financial Results

MOUNTAIN VIEW, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 28, 2020 . Commenting on the recently completed quarter and the business environment created by the COVID-19 pandemic, David I.
May 05, 2020

Patrick Mercer

Patrick Mercer marco.guevara@… Mon, 05/04/2020 - 22:17 Patrick Mercer Chief Operating Officer Mr. Mercer serves as our Chief Operating Officer.  He joined the Company in 2018, bringing over 20 years of experience serving in multiple operational positions across …
Show more

 IRIDEX Frequently Asked Questions

  • When was IRIDEX founded?

    IRIDEX was founded in 1989.

  • How many employees does IRIDEX have?

    IRIDEX has 94 employees.

  • What is IRIDEX revenue?

    Latest IRIDEX annual revenue is $43.4 m.

  • What is IRIDEX revenue per employee?

    Latest IRIDEX revenue per employee is $462.2 k.

  • Who are IRIDEX competitors?

    Competitors of IRIDEX include Lumibird, LPKF Laser & Electronics and Asclepion.

  • Where is IRIDEX headquarters?

    IRIDEX headquarters is located at 1212 Terra Bella Ave, Mountain View.

  • Where are IRIDEX offices?

    IRIDEX has an office in Mountain View.

  • How many offices does IRIDEX have?

    IRIDEX has 1 office.